SCHEMBL5565548

SCHEMBL5565548

CC(=O)c1ccc(S(=O)(=O)NO[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 4/20 0.49
MAPT P10636 2/20 0.49
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
HPGD P15428 2/20 0.46
FFAR4 Q5NUL3 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
POLB P06746 2/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2C9 P11712 1/20 0.42
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
LMNA P02545 3/20 0.41
ALOX12 P18054 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1548097 0.81 GAA (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL14349613 0.80 ALDH1A1 (0.54) MEN1KMT2AALDH1A1MAPTCA1
SCHEMBL1547465 0.80 ALDH1A1 (0.41) ALDH1A1CA1CA2LMNATSHR
SCHEMBL5565433 0.76 CA12 (0.56) MEN1KMT2AALDH1A1MAPTCA12
SCHEMBL3643243 0.73 ALDH1A1 (0.58) MEN1KMT2AALDH1A1MAPTCA12
SCHEMBL5565789 0.70 CA12 (0.61) MEN1KMT2AALDH1A1MAPTCA12
SCHEMBL11696351 0.70 ALDH1A1 (0.55) MEN1KMT2AALDH1A1MAPTCA12
SCHEMBL14676354 0.70 MEN1 (0.51) MEN1KMT2AALDH1A1MAPTCA12
SCHEMBL936407 0.69 MAPT (0.53) KMT2AALDH1A1MAPTCA12CA9
SCHEMBL5564217 0.69 CA12 (0.55) MEN1KMT2AALDH1A1MAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 MEN1 2929/4885KMT2A 3609/4885ALDH1A1 1653/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 MEN1 2929/4885KMT2A 3609/4885ALDH1A1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.